U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C20H25N3O4.C4H6O5
Molecular Weight 505.5176
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEMONOXACIN MALATE ANHYDROUS

SMILES

OC(CC(O)=O)C(O)=O.COC1=C(C=CC2=C1N(C=C(C(O)=O)C2=O)C3CC3)N4C[C@@H](C)C[C@H](N)C4

InChI

InChIKey=YMVJINCWEIPOFL-FXMYHANSSA-N
InChI=1S/C20H25N3O4.C4H6O5/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26;5-2(4(8)9)1-3(6)7/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26);2,5H,1H2,(H,6,7)(H,8,9)/t11-,12-;/m0./s1

HIDE SMILES / InChI
Nemonoxacin is a non-fluorinated quinolone antibiotic in clinical development in an oral and intravenous formulation. It exhibits potent antibacterial activities against Gram-positive, Gram-negative, and atypical pathogens, especially methicillin-resistant Staphylococcus aureus. The molecule inhibits bacterial DNA synthesis by forming a ternary complex with a DNA molecule and gyrase and topoisomerase IV enzymes, thus blocking bacterial DNA supercoiling. Nemonoxacin is developed by TaiGen Biotechnology Company and has reached worldwide approval in 2014 and is marketed under the name Taigexyn®.

Approval Year

PubMed

PubMed

TitleDatePubMed
In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone.
2010-11
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
2010-11
Gateways to clinical trials.
2010-06
In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
2009-12
Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.
2009-08
Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.
2009-07
New antibiotics for antibiotic-resistant bacteria.
2009-05-28
Patents
Name Type Language
NEMONOXACIN MALATE ANHYDROUS
Common Name English
BUTANEDIOIC ACID, 2-HYDROXY-, COMPD. WITH 7-((3S,5S)-3-AMINO-5-METHYL-1-PIPERIDINYL)-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID
Preferred Name English
Nemonoxacin malate [WHO-DD]
Common Name English
BUTANEDIOIC ACID, 2-HYDROXY-, COMPD. WITH 7-((3S,5S)-3-AMINO-5-METHYL-1-PIPERIDINYL)-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID (1:1)
Common Name English
Code System Code Type Description
PUBCHEM
49863435
Created by admin on Mon Mar 31 21:26:56 GMT 2025 , Edited by admin on Mon Mar 31 21:26:56 GMT 2025
PRIMARY
SMS_ID
300000038179
Created by admin on Mon Mar 31 21:26:56 GMT 2025 , Edited by admin on Mon Mar 31 21:26:56 GMT 2025
PRIMARY
CAS
951163-60-3
Created by admin on Mon Mar 31 21:26:56 GMT 2025 , Edited by admin on Mon Mar 31 21:26:56 GMT 2025
PRIMARY
FDA UNII
24502Q4NWQ
Created by admin on Mon Mar 31 21:26:56 GMT 2025 , Edited by admin on Mon Mar 31 21:26:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID00241759
Created by admin on Mon Mar 31 21:26:56 GMT 2025 , Edited by admin on Mon Mar 31 21:26:56 GMT 2025
PRIMARY